Om

Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies for cancer. The company’s current work centers on immune-modulating treatments designed to address solid tumors, with a particular emphasis on CD47-blockade technology and its candidate IBA101, a humanized anti-CD47 monoclonal antibody. Liminatus Pharma is also associated with broader oncology research efforts that explore next-generation immune-based approaches and CAR-T platforms for difficult-to-treat cancers. Its business is concentrated in the biotechnology and healthcare sectors, where it contributes to the development of targeted cancer therapies intended to expand treatment options in oncology. Founded in 2018 and headquartered in California, Liminatus Pharma remains focused on advancing clinical research and therapeutic development for patients with unmet needs in cancer care.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I LIMINATUS PHARMA MED ENDAVU: Køb Liminatus Pharma ($LIMN) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Liminatus Pharma, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.